Methods and compositions for enhancing the efficacy and specificity of RNA silencing
The present invention provides methods of enhancing the efficacy and specificity of RNA silencing. The invention also provides compositions for mediating RNA silencing. In particular, the invention provides siRNAs, siRNA-like molecules, shRNAs, vectors and transgenes having improved specificity and efficacy in mediating silencing of a target gene. Therapeutic methods are also featured.
1. An engineered pre-miRNA comprising an asymmetrical substituted siRNA duplex comprising one or more substituted base pairs, the duplex comprising a sense strand and an antisense strand, each strand having a 5′ end and a 3′ end, and wherein the one or more substituted base pairs are within 5 base pairs from the antisense strand 5′ (AS 5′) end and the sense strand 3′ (S 3′) end and are selected from the group consisting of a mismatched base pair, a wobble base pair, a base pair comprising a rare nucleotide and a base pair comprising a modified amino-purine nucleotide, such that entry of the antisense strand into a RISC complex is promoted relative to the sense strand; such that the antisense strand preferentially guides cleavage of a desired target mRNA by the RISC complex, wherein the engineered pre-miRNA is made by:
(a) selecting a first siRNA duplex comprising a sense strand and an antisense strand, each strand having a 5′ and a 3′ end, wherein the first siRNA duplex directs cleavage by a RISC complex at a phosphodiester bond within a desired target mRNA, the first siRNA duplex having a base pairing strength within 5 base pairs from the antisense strand 5′ (AS 5′) end and the sense strand 3′ (S 3′) end relative to a base pairing strength within 5 base pairs from the antisense strand 3′ (AS 3′) and the sense strand 5′ (S 5′) end, and
(b) synthesizing the engineered pre-miRNA comprising the substituted siRNA duplex comprising one or more substituted base pairs with respect to the first siRNA duplex, wherein the substituted siRNA duplex comprises a sense strand and an antisense strand, each strand having a 5′ and a 3′ end, and wherein the substituted siRNA duplex directs cleavage by the RISC complex at the same phosphodiester bond within the desired target mRNA as the first siRNA duplex, the substituted siRNA duplex having a base pairing strength within 5 base pairs from the AS 5′ and the S 3′ end and a base pairing strength within 5 base pairs from the AS 3′ and the S 5′ end, wherein the one or more substituted base pairs are within 5 base pairs from the AS 5′ and the S 3′ end and are selected from the group consisting of a mismatched base pair, a wobble base pair, and a base pair comprising a rare nucleotide and a base pair comprising a modified amino-purine nucleotide, such that the base pairing strength within 5 base pairs from the AS 5′ and the S 3′ end of the substituted siRNA duplex relative to the base pairing strength within 5 base pairs from the AS 3′ and the S '5 end of the substituted siRNA duplex is lessened as compared to the base pairing strength within AS 5′ and the S 3′ end of the first siRNA duplex relative to the base pairing strength between the AS 3′ and the S 5′ end of the first siRNA duplex.
2. A vector encoding the pre-miRNA of claim 1 .
3. A pri-miRNA comprising the pre-miRNA of claim 2 .
4. A vector encoding the pri-miRNA of claim 3 .
5. A cell comprising the vector of claim 2 or 4 .
6. The cell of claim 5 , which is a mammalian cell.
7. The cell of claim 5 , which is a human cell.
8. The engineered pre-miRNA of claim 1 , wherein the one or more substituted base pairs comprise at least one mismatched base pair.
9. The engineered pre-miRNA of claim 8 , wherein the mismatched base pair is selected from the group consisting of G:A, C:A, C:U, G:G, A:A, C:C and U:U.
10. The engineered pre-miRNA of claim 8 , wherein the mismatched base pair is selected from the group consisting of G:A, C:A, C:T, G:G, A:A, C:C and U:T.
11. The engineered pre-miRNA of claim 1 , wherein the one or more substituted base pairs comprise at least one wobble base pair.
12. The engineered pre-miRNA of claim 11 , wherein the wobble base pair is G:U.
13. The engineered pre-miRNA of claim 11 , wherein the wobble base pair is G:T.
14. The engineered pre-miRNA of claim 1 , wherein the one or more substituted base pairs comprise at least one base pair comprising a rare nucleotide.
15. The engineered pre-miRNA of claim 14 , wherein the rare nucleotide is inosine (I).
16. The engineered pre-miRNA of claim 15 , wherein the base pair is selected from the group consisting of an I:A, I:U and I:C.
17. The engineered pre-miRNA of claim 1 , wherein the one or more substituted base pairs comprise at least one base pair comprising a modified amino-purine nucleotide.
18. The engineered pre-miRNA of claim 17 , wherein the modified amino-purine nucleotide is selected from the group consisting of 2-amino-G, 2-amino-A, 2,6-diamino-G, and 2,6-diamino-A.
19. A pharmaceutical composition comprising the engineered pre-miRNA of claim 1 wherein the target desired mRNA is expressed in a human cell.
20. A pharmaceutical composition comprising the vector of claim 2 wherein the desired target mRNA is expressed in a human cell.
21. A pharmaceutical composition comprising the pri-miRNA of claim 3 wherein the desired target mRNA is expressed in a human cell.
22. A pharmaceutical composition comprising the vector of claim 4 wherein the desired target mRNA is expressed in a human cell.
23. A pharmaceutical composition comprising the cell of claim 5 wherein the desired target mRNA is expressed in a human cell.
24. A pharmaceutical composition comprising the cell of claim 6 wherein the desired target mRNA is expressed in a human cell.
25. A pharmaceutical composition comprising the cell of claim 7 wherein the desired target mRNA is expressed in a human cell.
26. A pharmaceutical composition comprising the engineered pre-miRNA of claim 8 wherein the desired target mRNA is expressed in a human cell.
27. A pharmaceutical composition comprising the engineered pre-miRNA of claim 9 wherein the desired target mRNA is expressed in a human cell.
28. A pharmaceutical composition comprising the engineered pre-miRNA of claim 10 wherein the desired target mRNA is expressed in a human cell.
29. A pharmaceutical composition comprising the engineered pre-miRNA of claim 11 wherein the desired target mRNA is expressed in a human cell.
30. A pharmaceutical composition comprising the engineered pre-miRNA of claim 12 wherein the desired target mRNA is expressed in a human cell.
31. A pharmaceutical composition comprising the engineered pre-miRNA of claim 13 wherein the desired target mRNA is expressed in a human cell.
32. A pharmaceutical composition comprising the engineered pre-miRNA of claim 14 wherein the desired target mRNA is expressed in a human cell.
33. A pharmaceutical composition comprising the engineered pre-miRNA of claim 15 wherein the desired target mRNA is expressed in a human cell.
34. A pharmaceutical composition comprising the engineered pre-miRNA of claim 16 wherein the desired target mRNA is expressed in a human cell.
35. A pharmaceutical composition comprising the engineered pre-miRNA of claim 17 wherein the desired target mRNA is expressed in a human cell.
36. A pharmaceutical composition comprising the engineered pre-miRNA of claim 18 wherein the desired target mRNA is expressed in a human cell.